Quick Facts
  • Primary Location:
    Fox Chase Cancer Center
  • Expertise:
    Research
    Chemoradiation
  • Speciality:
    Radiation Oncology
  • Gender:
    Female
  • Language:
    English
  • Med School:
    West Virginia University School of Medicine

Get to Know Dr. Sameera Kumar

Dr. Sameera Kumar is a radiation oncologist and associate professor at Fox Chase Cancer Center in Philadelphia. She focuses on the treatment of thoracic diseases such as mesothelioma, lung cancer, esophageal cancer and thymoma.

Since joining the cancer specialists at Fox Chase in 2018, Kumar has been lauded for her ability to blend clinical and academic skills and for the patient-first priority she brings to everything she does.

In 2020, Kumar was involved in one of the first national studies that outlined best medical practices to protect vulnerable cancer patients during the recent COVID-19 pandemic. The report was a collaborative effort undertaken by several facilities in anticipation of the pandemic climax.

Kumar co-authored a narrative review in 2021 that detailed the efficacy of different radiation techniques as part of a multidisciplinary treatment plan for patients with pleural mesothelioma.

She was also part of another study at Fox Chase involving non-small cell lung cancer patients that has helped doctors predict which tumor factors are most likely to lead to success with stereotactic body radiation therapy.

Contact Sameera S. Kumar

Specialties of Dr. Sameera S. Kumar

  • Pleural mesothelioma
  • Lung cancer
  • Esophageal cancer
  • Thymoma
  • Lung metastases
  • Stereotactic body radiation therapy

Dr. Sameera S. Kumar’s Experience and Education

  • Fox Chase Cancer Center
  • University of Kentucky College of Medicine (Residency)
  • West Virginia University School of Medicine (M.D.)

Awards and Certifications

  • Board certified in radiation oncology

Publications of Dr. Sameera S. Kumar

  • Kumar, S. et al. (2017, November 1). Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics.
  • Kumar, S.S. et al. (2017, September 4). Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. Frontiers in Oncology.
  • Verma, V. et al. (2017, February 15). Multi-institutional experience of stereotactic body radiotherapy for large non-small cell lung tumors. Cancer.
  • Kumar, S.S. et al. (2013, February). Radiation necrosis: Now you see it, now you don’t. Applied Radiology.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?